Article
Medicine, General & Internal
Hengwei Wu, Jimin Shi, Yi Luo, Yamin Tan, Mingming Zhang, Xiaoyu Lai, Jian Yu, Lizhen Liu, Huarui Fu, He Huang, Yanmin Zhao
Summary: In this study, the clinical response to ruxolitinib in patients with steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation was investigated, and its safety profile was evaluated during the treatment course. The majority of patients treated with ruxolitinib showed significant treatment responses with a relatively well-tolerated safety profile, with lung involvement and matched related donors being associated with less favorable treatment response.
Review
Immunology
Shan Jiang, Han Yan, Xuan Lu, Ruowen Wei, Haoran Chen, Ao Zhang, Wei Shi, Linghui Xia
Summary: In recent years, haploidentical transplantation technology has advanced, leading to increased availability of donors and improved conditions for elderly AML patients to receive allogeneic hematopoietic stem cell transplantation. This article summarizes the pre-transplant assessment methods, various sources of donors, conditioning regimens, and post-transplant complication management based on large-scale clinical studies.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Giuseppe Lia, Luisa Giaccone, Sarah Leone, Benedetto Bruno
Summary: Endothelial cell dysfunction after hematopoietic stem cell transplant can lead to early complications such as GVHD, TA-TMA, and SOS, which remain a major obstacle for successful transplant. While various biomarkers have been studied for detecting endothelial cell dysfunction post-transplant, validation is still limited.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Linus Angenendt, Isabel Hilgefort, Jan-Henrik Mikesch, Bernhard Schlueter, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes, Christoph Schliemann
Summary: High posttransplant magnesium levels have been independently associated with a lower relapse rate, an increased risk of acute graft-versus-host disease, and higher non-relapse mortality in patients with acute myeloid leukemia.
ANNALS OF HEMATOLOGY
(2021)
Article
Immunology
Sun Yao, Chen Jianlin, Qiao Zhuoqing, Li Yuhang, Hu Jiangwei, Hu Guoliang, Ning Hongmei, Zhang Bin, Hu Liangding
Summary: This case report describes a patient with treated secondary AML who received tislelizumab in combination with azacitidine. While the patient achieved complete remission, they also experienced serious immune-related adverse events and graft vs. host disease, ultimately leading to death. This highlights the safety concerns of combining anti-PD-1 antibodies with azacitidine after allo-HSCT, particularly the risk of GVHD.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Yiouli P. Ktena, Margarita Dionysiou, Lukasz P. Gondek, Kenneth R. Cooke
Summary: Epigenetics studies the regulation of gene expression without altering the DNA sequence. It plays a vital role in cellular homeostasis, differentiation, hematopoiesis, and immunity. Epigenetic modifications can be heritable and reversible, and there is growing interest in their potential role in allogeneic hematopoietic transplantation. This review provides an overview of epigenetic modifications and their functions, focusing on hematopoiesis and immunity in the context of allogeneic hematopoietic stem cell transplantation.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Arjun Datt Law, Sita Bhella, Ivan Pasic, Wilson Lam, Fotios V. Michelis, Armin Gerbitz, Auro Viswabandya, Rajat Kumar, Jeffrey H. Lipton, Jonas Mattsson, Dennis Dong Hwan Kim
Summary: Avascular necrosis (AVN) is a severe complication of HCT, with younger age and moderate-severe chronic GvHD identified as key risk factors. A risk score model effectively stratified patients into low, intermediate, and high risk groups for predicting AVN risk.
ANNALS OF HEMATOLOGY
(2021)
Review
Immunology
Masahiro Miyata, Kazunobu Ichikawa, Eri Matsuki, Masafumi Watanabe, Daniel Peltier, Tomomi Toubai
Summary: Acute kidney injury is a common complication of allogeneic hematopoietic cell transplantation and can be caused by multiple factors. Recent studies suggest that graft-versus-host disease may attack the kidneys and contribute to the development of renal injury.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Robert Puckrin, Mona Shafey, Jan Storek
Summary: Although the use of allogeneic HCT for CLL has declined, it remains important for high-risk or heavily pretreated patients. The procedure carries risks of GVHD, infection, and NRM, but advancements have made it safer and more effective. This review focuses on evidence-based strategies to maximize benefit and minimize toxicity of allogeneic HCT for CLL.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biophysics
Miriam Sanchez-Escamilla, Jessica Flynn, Sean Devlin, Molly Maloy, Samira A. Fatmi, Ana Alarcon Tomas, Silvia Escribano-Serrat, Doris Ponce, Craig S. Sauter, Sergio A. Giralt, Michael Scordo, Miguel-Angel Perales
Summary: The Endothelial Activation and Stress Index (EASIX) is a prognostic tool that predicts non-relapse mortality (NRM) and overall survival (OS) at the onset of acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). This study evaluated the EASIX score at different time points pre- and post-HCT and found that high EASIX scores were significantly associated with poorer overall outcomes, independent of other factors. EASIX provides an independent and easily accessible tool to predict outcomes for patients undergoing HCT.
BONE MARROW TRANSPLANTATION
(2023)
Article
Gastroenterology & Hepatology
Yannouck F. van Lier, Jael Vos, Bianca Blom, Mette D. Hazenberg
Summary: Patients with hematological malignancies often undergo allogeneic hematopoietic cell transplantation (HCT) to cure their condition. HCT can disrupt the intestinal microbiota, leading to poor transplant outcomes and graft-versus-host disease (GvHD). Strategies such as dietary interventions, antibiotic stewardship, and fecal microbiota transplantation are being explored to prevent or treat microbiota injury and GvHD. This review provides insights into the role of microbiome in GvHD pathogenesis and summarizes interventions for microbiota injury prevention and treatment.
Article
Surgery
Cecile Chague, Thomas Gautier, Ludivine Dal Zuffo, Jean-Paul Pais de Barros, Audrey Wetzel, Georges Tarris, Gaetan Pallot, Laurent Martin, Severine Valmary-Degano, Valerie Deckert, Laurent Lagrost, Etienne Daguindau, Philippe Saas
Summary: This study found that HDL deficiency leads to LPS accumulation and exacerbates aGVHD. However, administration of HDL isolated from human plasma significantly decreases the mortality and severity of aGVHD. HDL infusion also plays an important role in mitigating liver aGVHD by reducing immune infiltration and inflammation.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Review
Oncology
Li Xuan, Qifa Liu
Summary: Relapse is still the main reason for treatment failure in AML patients undergoing allo-HSCT. Evidence suggests that maintenance therapy post-transplantation, particularly targeted drugs like hypomethylating agents, FLT3 inhibitors, and isocitrate dehydrogenase inhibitors, could benefit AML patients, especially those at high risk.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Hematology
Nelli Bejanyan, John Rogosheske, Qing Cao, Aleksandr Lazaryan, Shernan Holtan, Celalettin Ustun, Pamala Jacobson, Margaret MacMillan, Daniel J. Weisdorf, John Wagner, Mukta Arora, Claudio G. Brunstein
Summary: Higher weight-based MMF dose can reduce the risk of acute GVHD after allogeneic hematopoietic cell transplantation, but may increase the risk of relapse. This dose had no significant impact on engraftment, chronic GVHD, or survival. Prospective studies are needed to optimize MMF dosing after HCT.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Article
Cell & Tissue Engineering
Servais Sophie, Beguin Yves, Baron Frederic
Summary: AlloHSCT offers the best chance for durable remission in older patients with AML, but it remains a difficult decision for hematologists due to potential toxicity and complex needs.
STEM CELLS TRANSLATIONAL MEDICINE
(2022)
Article
Hematology
Shannon R. McCurdy, Vedran Radojcic, Hua-Ling Tsai, Ante Vulic, Elizabeth Thompson, Sanja Ivcevic, Christopher G. Kanakry, Jonathan D. Powell, Brian Lohman, Djamilatou Adom, Sophie Paczesny, Kenneth R. Cooke, Richard J. Jones, Ravi Varadhan, Heather J. Symons, Leo Luznik
Summary: This study used machine learning to analyze the immunologic signatures associated with posttransplant outcomes in bone marrow transplantation using PTCy. The results identified specific lymphocyte subsets that predict clinical outcomes and offered new insights into the influence of PTCy on alloimmune responses. The study highlights the importance of NK cell counts and CD4(+) regulatory T cells in patient survival and acute graft-versus-host disease. The findings contribute to the discovery of biomarkers in bone marrow transplantation and provide directions for future therapeutic interventions.
Article
Multidisciplinary Sciences
Yongyao Fu, Abigail Pajulas, Jocelyn Wang, Baohua Zhou, Anthony Cannon, Cherry Cheuk Lam Cheung, Jilu Zhang, Huaxin Zhou, Amanda Jo Fisher, David T. Omstead, Sabrina Khan, Lei Han, Jean-Christophe Renauld, Sophie Paczesny, Hongyu Gao, Yunlong Liu, Lei Yang, Robert M. Tighe, Paula Licona-Limon, Richard A. Flavell, Shogo Takatsuka, Daisuke Kitamura, Jie Sun, Basar Bilgicer, Catherine R. Sears, Kai Yang, Mark H. Kaplan
Summary: The role of IL-9 in the tumor microenvironment and its effects on macrophages have been investigated. The study shows that IL-9 promotes the expansion of pulmonary macrophages and targeting the IL-9R/arginase 1 axis restricts tumor growth, suggesting that this cytokine pathway could be a potential therapeutic target for lung cancer.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, Research & Experimental
Timothy S. Olson, Benjamin F. Frost, Jamie L. Duke, Marian Dribus, Hongbo M. Xie, Zachary D. Prudowsky, Elissa Furutani, Jonas Gudera, Yash B. Shah, Deborah Ferriola, Amalia Dinou, Ioanna Pagkrati, Soyoung Kim, Yixi Xu, Meilun He, Shannon Zheng, Sally Nijim, Ping Lin, Chong Xu, Taizo A. Nakano, Joseph H. Oved, Beatriz M. Carreno, Yung-Tsi Bolon, Shahinaz M. Gadalla, Steven Ge Marsh, Sophie Paczesny, Stephanie J. Lee, Dimitrios S. Monos, Akiko Shimamura, Alison A. Bertuch, Loren Gragert, Stephen R. Spellman, Daria Babushok
Summary: This study evaluated somatic HLA loss in patients with acquired aplastic anemia (AA) and identified HLA alleles associated with the development of AA. The results showed that HLA alleles increase the risk of AA, but do not affect response to immunosuppression or transplant outcomes. Higher pathogenicity alleles are associated with higher rates of clonal evolution in AA patients.
Article
Medicine, Research & Experimental
Baskar Ramdas, Palam Lakshmi Reddy, Raghuveer Singh Mali, Santhosh Kumar Pasupuleti, Ji Zhang, Mark R. Kelley, Sophie Paczesny, Chi Zhang, Reuben Kapur
Summary: Heterozygous mutations in FLT3(ITD), TET2, and DNMT3A are associated with hematologic malignancies in humans. This study investigated the co-occurrence of these mutations in a mouse model of acute myeloid leukemia (AML) and found that mice with all three mutations showed an aggressive form of AML. The gene expression pattern in these mice was similar to the human TFD gene signature at the single-cell RNA level. Importantly, the TFD-driven AML responded to a combination of drugs in both mouse and patient-derived models.
Meeting Abstract
Hematology
Chao-Yie Yang, Xinrui Yuan, Hua Jiang, Jason C. Rech, Denggang Fu, Aaron Robida, Krishani Rajanayake, Hebao Yuan, Bo Wen, Duxin Sun, Krishnapriya Chinnaswamy, Jeanne A. Stuckey, Sophie Paczesny
Meeting Abstract
Hematology
Denggang Fu, Hua Jiang, Sophie Paczesny
Article
Oncology
Pietro Crivello, Esteban Arrieta-Bolanos, Meilun He, Tao Wang, Stephanie Fingerson, Shahinaz M. Gadalla, Sophie Paczesny, Steven G. E. Marsh, Stephanie L. J. Lee, Stephen R. Spellman, Yung-Tsi Bolon, Katharina Fleischhauer
Summary: This study found that immunopeptidome divergence is a determinant of T-cell alloreactivity and clinical tolerability in single class I HLA-mismatched unrelated donor hematopoietic cell transplantation. Using hierarchical clustering of peptide-binding motifs, the authors classified 68.1% of the HLA-mismatched transplants as matched or mismatched. Mismatched transplants were associated with lower overall survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Carrie L. Kitko, Catherine M. Bollard, Mitchell S. Cairo, Joseph Chewning, Terry J. Fry, Michael A. Pulsipher, Shalini Shenoy, Donna A. Wall, John E. Levine
Summary: Since 2013, the Children's Oncology Group cellular therapy-based trials have advanced the field and set new standards of care for pediatric cancer. Key findings include improved survival with tandem autologous transplant for neuroblastoma and atypical teratoid/rhabdoid brain tumors, safer single umbilical cord blood donor compared to two donors, lack of survival improvement with killer immunoglobulin receptor (KIR) mismatched donors for pediatric acute myeloid leukemia, and the importance of minimal residual disease assessment for predicting relapse in acute lymphoblastic leukemia. Future plans include optimizing donor selection, using engineered cellular therapies, and developing better treatments for therapy toxicities.
PEDIATRIC BLOOD & CANCER
(2023)
Editorial Material
Hematology
John E. Levine
Article
Hematology
Santosh Putta, Bradford A. Young, John E. Levine, Ran Reshef, Ryotaro Nakamura, Christopher Strouse, Miguel -Angel Perales, Alan Howard, Polly Pine, Ju Shi, Peixin Zhang, Vincent T. Ho, Wael Saber
Summary: This study aimed to determine blood biomarkers that could identify high-risk patients for hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) shortly after hematopoietic cell transplantation (HCT). The study found that a combination of up to 5 protein biomarkers may provide a prognostic tool for identifying patients at risk for VOD/SOS.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Review
Hematology
Alan Bidgoli, Brittany Paige DePriest, Maedeh Vakili Saatloo, Hua Jiang, Denggang Fu, Sophie Paczesny
Summary: Hematopoietic cell transplantation is a potentially curative treatment for hematologic and nonhematologic disorders. Graft-versus-host disease is a major complication post-transplantation, and biomarkers play a significant role in disease diagnosis and management.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Hannah-Lise T. Schofield, Vanessa A. Fabrizio, Suzanne Braniecki, Wendy Pelletier, Hesham Eissa, Beverly Murphy, Joseph Chewning, Karen D. Barton, Leanne M. Embry, John E. Levine, Kirk R. Schultz, Kristin M. Page
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Meeting Abstract
Cell Biology
Johannes Schetelig, Henning Baldauf, Falk Heidenreich, Jorinde D. Hoogenboom, Stephen Spellman, Aleksandr Kulagin, Thomas Schroeder, Henrik Sengeloev, Peter Dreger, Edouard Forcade, Jan Vydra, Eva-Maria Wagner-Drouet, Goda Choi, Shankara Paneesha, Nuno Miranda, Alina Tanase, Liesbeth C. de Wreede, Vinzenz Lange, Alexander H. Schmidt, Juergen Sauter, Stephanie Lee, Yung-Tsi Bolon, Meilun He, Steven G. E. Marsh, Shahinaz Gadalla, Sophie Paczesny, Annalisa Ruggeri, Christian Chabannon, Katharina Fleischhauer
Meeting Abstract
Cell Biology
Pietro Crivello, Esteban Arrieta-Bolanos, Meilun He, Tao Wang, Shahinaz M. Gadalla, Sophie Paczesny, Steven G. E. Marsh, Stephanie J. Lee, Stephen R. Spellman, Yung-Tsi Bolon, Katharina Fleischhauer
Meeting Abstract
Cell Biology
Esteban Arrieta-Bolanos, Pietro Crivello, Meilun He, Tao Wang, Shahinaz Gadalla, Sophie Paczesny, Steven G. E. Marsh, Stephanie J. Lee, Stephen R. Spellman, Yung-Tsi Bolon, Katharina Fleischhauer
